You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

鹽野製藥(SGIOY.US)正在尋求日本批準新冠疫苗S-268019

格隆匯 11-24 22:44
格隆匯11月24日丨鹽野製藥(SGIOY.US)週四表示，已在日本申請批準其實驗性COVID-19疫苗。兩天前，日本監管機構緊急批準鹽野製藥新冠口服治療藥物，這是日本國內製藥企業首次獲得批準的新冠口服治療藥物。 鹽野木在一份聲明中說，重組蛋白疫苗S-268019的申請是基於日本五項臨牀試驗的結果。 該公司試圖將這種疫苗作爲對抗新冠的初級疫苗和增強劑進行營銷。 鹽野木上個月上調了全年銷售預期，因預期該公司將獲得監管部門的批準。該公司已經簽署了向日本政府出售約100萬劑疫苗的協議，目前正在等待批準。該公司還獲得了美國政府的資金，用於全球試驗。
Relevant Recommendation
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.